In high-risk patients with T2D (ie, those with atheroscleroticcardiovascular disease (ASCVD) and/or CKD), SGLT2 inhibitors should beinitiated to reduce the risk of CV events (Table 2). Here, SLC5A2 is linked to type 2 diabetes mellitus.